Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | CTSK | P43235 | 3/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | CTSL | P07711 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16968587 | 0.81 | CYP1A2 (0.41) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL3363650 | 0.78 | AAK1 (0.43) | CTSKAAK1KMT2ACTSL | |
| SCHEMBL1414251 | 0.78 | AAK1 (0.43) | CTSKAAK1KMT2ACTSL | |
| SCHEMBL21277689 | 0.77 | CYP1A2 (0.38) | CYP1A2CYP2C9CYP2C19HTTCTSK | |
| SCHEMBL3120243 | 0.75 | AAK1 (0.43) | CTSKAAK1KMT2AMEN1CTSL | |
| SCHEMBL26782180 | 0.75 | CA2 (0.39) | CTSKAAK1KMT2AMEN1TSHR | |
| SCHEMBL3117394 | 0.75 | AAK1 (0.44) | CTSKAAK1KMT2AALDH1A1CTSL | |
| SCHEMBL22862622 | 0.74 | AAK1 (0.46) | CTSKAAK1KMT2A | |
| SCHEMBL28964316 | 0.74 | HDAC4 (0.44) | CTSKAAK1KMT2AMEN1 | |
| SCHEMBL25989692 | 0.73 | AAK1 (0.42) | CTSKAAK1KMT2ATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170260180-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | VITAE PHARMACEUTICALS, LLC | 2017-09-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170260180-A1 | DIHYDROPYRROLOPYRIDINE INHIBITORS OF ROR-GAMMA | RORC, RORB, RORA | CYP1A2 128/4885CYP2C9 399/4885CYP2C19 451/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.